Funder
Cyberonics
AstraZeneca
Merck and Company
Agency for Healthcare Research and Quality
AstraZeneca Pharmaceuticals
Cephalon
Eli Lilly and Company
National Institute of Mental Health
Pfizer Inc.
Sunovion Pharmaceuticals
Allergan Inc.
Avanir Pharmaceuticals
Bristol-Myers Squibb Company
Forest Pharmaceuticals
Janssen Pharmaceuticals
Merck & Co.
Teva Pharmaceutical
Abbott Laboratories, Inc.
GlaxoSmithKline
Otsuka Pharmaceutical
American Psychiatric Publishing
Subject
Psychiatry and Mental health,Clinical Psychology
Reference38 articles.
1. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up;Altshuler;Am. J. Psychiatry,2003
2. Switch rates during acute treatment for bipolar II depression with lithium, sertraline, or the two combined: a randomized double-blind comparison;Altshuler;Am. J. Psychiatry,2017
3. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study;Amsterdam;J. Affect. Disord.,2015
4. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders;Baldessarini;Psychiatr. Serv.,2007
5. Treatment options for acute depression in bipolar disorder;Bauer;Bipolar Disord.,2012
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献